Noninvasive disease monitoring and risk stratification by circulating tumor DNA (ctDNA)
profiling has become a potential novel strategy for patient management in B-cell lymphoma …

Secondary central nervous system (CNS) lymphoma (SCNSL) is defined by the involvement
of the CNS, either at the time of initial diagnosis of systemic lymphoma or in the setting of …

PURPOSE Clinical outcomes of patients with CNS lymphomas (CNSLs) are remarkably
heterogeneous, yet identification of patients at high risk for treatment failure is challenging …

Primary diffuse large B-cell (DLBCL) lymphoma of the central nervous system
(CNS)(PCNSL) is a new lymphoma entity, recognized by the 2017 WHO classification of …

Diagnosis of primary central nervous system lymphoma (PCNSL) is challenging, and
although brain biopsy remains the gold standard, cerebrospinal fluid (CSF) constitutes a …

Early diagnosis is crucial for the successful treatment of primary CNS lymphoma (PCNSL), a
rapidly progressing tumour. Suspicion raised on brain MRI must be confirmed by a …

The preclinical diagnosis and clinical practice for Alzheimer's disease (AD) based on liquid
biopsy have made great progress in recent years. As liquid biopsy is a fast, low-cost, and …

The current standard of diagnosing central nervous system (CNS) lymphoma is stereotactic
biopsy, however the procedure has a risk of surgical complication. Liquid biopsy of the CSF …

Simple Summary Primary central nervous system lymphoma (PCNSL) is an uncommon
disease accounting for around 3% of primary CNS tumors. PCNSL exhibits aggressive …

Detection and characterization of circulating tumor DNA (ctDNA) in body fluids has the
potential to revolutionize management of patients with lymphoma. Minimal access to …